Cystic fibrosis is a genetic disease that causes continuous lung infections and breathing problem over time. It is a progressive disease. The presence of imperfect gene causes a thick, sticky buildup of mucus in the lungs, intestine liver, pancreas, and other organs. The mucus in the lungs clogs airways and traps bacteria leading to infections that causes savior lung damage, and respiratory failure. The mucus prevents in the pancreas discharge the digestive enzymes that allow the body to break down food and absorb vital nutrients. This disease is caused by mutation in gene, cystic fibrosis trans membrane conductance regulator (CFTR) is a membrane protein in vertebrates, a protein required for regulating sweat, mucus and body secretions.

The global Cystic Fibrosis (CF) Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Cystic Fibrosis (CF) Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cystic Fibrosis (CF) Therapeutics.

Report Scope

The Cystic Fibrosis (CF) Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Cystic Fibrosis (CF) Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Cystic Fibrosis (CF) Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Cystic Fibrosis (CF) Therapeutics Market Report

Report Metric	Details
Report Name	Cystic Fibrosis (CF) Therapeutics Market
CAGR	5%
Segment by Type	Pancreatic enzyme supplements Mucolytics Bronchodilators CFTR modulators
Segment by Application	Oral drugs Inhaled drugs
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Vertex Pharmaceuticalsorporated, Gilead, AbbVie,, Novartis AG, F. Hoffmann-La Roche Ltd, Alaxia, Merck & Co., AIT (Advanced Inhalation Therapies), ALLERGAN, AstraZeneca, Teva Pharmaceutical Industries Ltd, Alcresta
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cystic Fibrosis (CF) Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Cystic Fibrosis (CF) Therapeutics Market report?

Ans: The main players in the Cystic Fibrosis (CF) Therapeutics Market are Vertex Pharmaceuticalsorporated, Gilead, AbbVie,, Novartis AG, F. Hoffmann-La Roche Ltd, Alaxia, Merck & Co., AIT (Advanced Inhalation Therapies), ALLERGAN, AstraZeneca, Teva Pharmaceutical Industries Ltd, Alcresta

What are the Application segmentation covered in the Cystic Fibrosis (CF) Therapeutics Market report?

Ans: The Applications covered in the Cystic Fibrosis (CF) Therapeutics Market report are Oral drugs, Inhaled drugs

What are the Type segmentation covered in the Cystic Fibrosis (CF) Therapeutics Market report?

Ans: The Types covered in the Cystic Fibrosis (CF) Therapeutics Market report are Pancreatic enzyme supplements, Mucolytics, Bronchodilators, CFTR modulators

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Cystic Fibrosis (CF) Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Pancreatic enzyme supplements

1.2.3 Mucolytics

1.2.4 Bronchodilators

1.2.5 CFTR modulators

1.3 Market by Application

1.3.1 Global Cystic Fibrosis (CF) Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Oral drugs

1.3.3 Inhaled drugs

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Cystic Fibrosis (CF) Therapeutics Market Perspective (2019-2030)

2.2 Cystic Fibrosis (CF) Therapeutics Growth Trends by Region

2.2.1 Global Cystic Fibrosis (CF) Therapeutics Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Cystic Fibrosis (CF) Therapeutics Historic Market Size by Region (2019-2024)

2.2.3 Cystic Fibrosis (CF) Therapeutics Forecasted Market Size by Region (2025-2030)

2.3 Cystic Fibrosis (CF) Therapeutics Market Dynamics

2.3.1 Cystic Fibrosis (CF) Therapeutics Industry Trends

2.3.2 Cystic Fibrosis (CF) Therapeutics Market Drivers

2.3.3 Cystic Fibrosis (CF) Therapeutics Market Challenges

2.3.4 Cystic Fibrosis (CF) Therapeutics Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Cystic Fibrosis (CF) Therapeutics Players by Revenue

3.1.1 Global Top Cystic Fibrosis (CF) Therapeutics Players by Revenue (2019-2024)

3.1.2 Global Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Players (2019-2024)

3.2 Global Cystic Fibrosis (CF) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Cystic Fibrosis (CF) Therapeutics Revenue

3.4 Global Cystic Fibrosis (CF) Therapeutics Market Concentration Ratio

3.4.1 Global Cystic Fibrosis (CF) Therapeutics Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Cystic Fibrosis (CF) Therapeutics Revenue in 2023

3.5 Cystic Fibrosis (CF) Therapeutics Key Players Head office and Area Served

3.6 Key Players Cystic Fibrosis (CF) Therapeutics Product Solution and Service

3.7 Date of Enter into Cystic Fibrosis (CF) Therapeutics Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Cystic Fibrosis (CF) Therapeutics Breakdown Data by Type

4.1 Global Cystic Fibrosis (CF) Therapeutics Historic Market Size by Type (2019-2024)

4.2 Global Cystic Fibrosis (CF) Therapeutics Forecasted Market Size by Type (2025-2030)

5 Cystic Fibrosis (CF) Therapeutics Breakdown Data by Application

5.1 Global Cystic Fibrosis (CF) Therapeutics Historic Market Size by Application (2019-2024)

5.2 Global Cystic Fibrosis (CF) Therapeutics Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Cystic Fibrosis (CF) Therapeutics Market Size (2019-2030)

6.2 North America Cystic Fibrosis (CF) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Cystic Fibrosis (CF) Therapeutics Market Size by Country (2019-2024)

6.4 North America Cystic Fibrosis (CF) Therapeutics Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Cystic Fibrosis (CF) Therapeutics Market Size (2019-2030)

7.2 Europe Cystic Fibrosis (CF) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Cystic Fibrosis (CF) Therapeutics Market Size by Country (2019-2024)

7.4 Europe Cystic Fibrosis (CF) Therapeutics Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Cystic Fibrosis (CF) Therapeutics Market Size (2019-2030)

8.2 Asia-Pacific Cystic Fibrosis (CF) Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Cystic Fibrosis (CF) Therapeutics Market Size by Region (2019-2024)

8.4 Asia-Pacific Cystic Fibrosis (CF) Therapeutics Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Cystic Fibrosis (CF) Therapeutics Market Size (2019-2030)

9.2 Latin America Cystic Fibrosis (CF) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Cystic Fibrosis (CF) Therapeutics Market Size by Country (2019-2024)

9.4 Latin America Cystic Fibrosis (CF) Therapeutics Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Cystic Fibrosis (CF) Therapeutics Market Size (2019-2030)

10.2 Middle East & Africa Cystic Fibrosis (CF) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Cystic Fibrosis (CF) Therapeutics Market Size by Country (2019-2024)

10.4 Middle East & Africa Cystic Fibrosis (CF) Therapeutics Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Vertex Pharmaceuticalsorporated

11.1.1 Vertex Pharmaceuticalsorporated Company Detail

11.1.2 Vertex Pharmaceuticalsorporated Business Overview

11.1.3 Vertex Pharmaceuticalsorporated Cystic Fibrosis (CF) Therapeutics Introduction

11.1.4 Vertex Pharmaceuticalsorporated Revenue in Cystic Fibrosis (CF) Therapeutics Business (2019-2024)

11.1.5 Vertex Pharmaceuticalsorporated Recent Development

11.2 Gilead

11.2.1 Gilead Company Detail

11.2.2 Gilead Business Overview

11.2.3 Gilead Cystic Fibrosis (CF) Therapeutics Introduction

11.2.4 Gilead Revenue in Cystic Fibrosis (CF) Therapeutics Business (2019-2024)

11.2.5 Gilead Recent Development

11.3 AbbVie,

11.3.1 AbbVie, Company Detail

11.3.2 AbbVie, Business Overview

11.3.3 AbbVie, Cystic Fibrosis (CF) Therapeutics Introduction

11.3.4 AbbVie, Revenue in Cystic Fibrosis (CF) Therapeutics Business (2019-2024)

11.3.5 AbbVie, Recent Development

11.4 Novartis AG

11.4.1 Novartis AG Company Detail

11.4.2 Novartis AG Business Overview

11.4.3 Novartis AG Cystic Fibrosis (CF) Therapeutics Introduction

11.4.4 Novartis AG Revenue in Cystic Fibrosis (CF) Therapeutics Business (2019-2024)

11.4.5 Novartis AG Recent Development

11.5 F. Hoffmann-La Roche Ltd

11.5.1 F. Hoffmann-La Roche Ltd Company Detail

11.5.2 F. Hoffmann-La Roche Ltd Business Overview

11.5.3 F. Hoffmann-La Roche Ltd Cystic Fibrosis (CF) Therapeutics Introduction

11.5.4 F. Hoffmann-La Roche Ltd Revenue in Cystic Fibrosis (CF) Therapeutics Business (2019-2024)

11.5.5 F. Hoffmann-La Roche Ltd Recent Development

11.6 Alaxia

11.6.1 Alaxia Company Detail

11.6.2 Alaxia Business Overview

11.6.3 Alaxia Cystic Fibrosis (CF) Therapeutics Introduction

11.6.4 Alaxia Revenue in Cystic Fibrosis (CF) Therapeutics Business (2019-2024)

11.6.5 Alaxia Recent Development

11.7 Merck & Co.

11.7.1 Merck & Co. Company Detail

11.7.2 Merck & Co. Business Overview

11.7.3 Merck & Co. Cystic Fibrosis (CF) Therapeutics Introduction

11.7.4 Merck & Co. Revenue in Cystic Fibrosis (CF) Therapeutics Business (2019-2024)

11.7.5 Merck & Co. Recent Development

11.8 AIT (Advanced Inhalation Therapies)

11.8.1 AIT (Advanced Inhalation Therapies) Company Detail

11.8.2 AIT (Advanced Inhalation Therapies) Business Overview

11.8.3 AIT (Advanced Inhalation Therapies) Cystic Fibrosis (CF) Therapeutics Introduction

11.8.4 AIT (Advanced Inhalation Therapies) Revenue in Cystic Fibrosis (CF) Therapeutics Business (2019-2024)

11.8.5 AIT (Advanced Inhalation Therapies) Recent Development

11.9 ALLERGAN

11.9.1 ALLERGAN Company Detail

11.9.2 ALLERGAN Business Overview

11.9.3 ALLERGAN Cystic Fibrosis (CF) Therapeutics Introduction

11.9.4 ALLERGAN Revenue in Cystic Fibrosis (CF) Therapeutics Business (2019-2024)

11.9.5 ALLERGAN Recent Development

11.10 AstraZeneca

11.10.1 AstraZeneca Company Detail

11.10.2 AstraZeneca Business Overview

11.10.3 AstraZeneca Cystic Fibrosis (CF) Therapeutics Introduction

11.10.4 AstraZeneca Revenue in Cystic Fibrosis (CF) Therapeutics Business (2019-2024)

11.10.5 AstraZeneca Recent Development

11.11 Teva Pharmaceutical Industries Ltd

11.11.1 Teva Pharmaceutical Industries Ltd Company Detail

11.11.2 Teva Pharmaceutical Industries Ltd Business Overview

11.11.3 Teva Pharmaceutical Industries Ltd Cystic Fibrosis (CF) Therapeutics Introduction

11.11.4 Teva Pharmaceutical Industries Ltd Revenue in Cystic Fibrosis (CF) Therapeutics Business (2019-2024)

11.11.5 Teva Pharmaceutical Industries Ltd Recent Development

11.12 Alcresta

11.12.1 Alcresta Company Detail

11.12.2 Alcresta Business Overview

11.12.3 Alcresta Cystic Fibrosis (CF) Therapeutics Introduction

11.12.4 Alcresta Revenue in Cystic Fibrosis (CF) Therapeutics Business (2019-2024)

11.12.5 Alcresta Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

Vertex Pharmaceuticalsorporated

Gilead

AbbVie

Novartis

F Hoffmann La Roche Ltd

Alaxia

Merck

AIT (Advanced Inhalation Therapies)

Allergan plc

Astrazeneca plc

Teva Pharmaceutical Industries Ltd

Alcresta

List of Tables

Table 1. Global Cystic Fibrosis (CF) Therapeutics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Pancreatic enzyme supplements

Table 3. Key Players of Mucolytics

Table 4. Key Players of Bronchodilators

Table 5. Key Players of CFTR modulators

Table 6. Global Cystic Fibrosis (CF) Therapeutics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 7. Global Cystic Fibrosis (CF) Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 8. Global Cystic Fibrosis (CF) Therapeutics Market Size by Region (2019-2024) & (US$ Million)

Table 9. Global Cystic Fibrosis (CF) Therapeutics Market Share by Region (2019-2024)

Table 10. Global Cystic Fibrosis (CF) Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 11. Global Cystic Fibrosis (CF) Therapeutics Market Share by Region (2025-2030)

Table 12. Cystic Fibrosis (CF) Therapeutics Market Trends

Table 13. Cystic Fibrosis (CF) Therapeutics Market Drivers

Table 14. Cystic Fibrosis (CF) Therapeutics Market Challenges

Table 15. Cystic Fibrosis (CF) Therapeutics Market Restraints

Table 16. Global Cystic Fibrosis (CF) Therapeutics Revenue by Players (2019-2024) & (US$ Million)

Table 17. Global Cystic Fibrosis (CF) Therapeutics Market Share by Players (2019-2024)

Table 18. Global Top Cystic Fibrosis (CF) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cystic Fibrosis (CF) Therapeutics as of 2023)

Table 19. Ranking of Global Top Cystic Fibrosis (CF) Therapeutics Companies by Revenue (US$ Million) in 2023

Table 20. Global 5 Largest Players Market Share by Cystic Fibrosis (CF) Therapeutics Revenue (CR5 and HHI) & (2019-2024)

Table 21. Key Players Headquarters and Area Served

Table 22. Key Players Cystic Fibrosis (CF) Therapeutics Product Solution and Service

Table 23. Date of Enter into Cystic Fibrosis (CF) Therapeutics Market

Table 24. Mergers & Acquisitions, Expansion Plans

Table 25. Global Cystic Fibrosis (CF) Therapeutics Market Size by Type (2019-2024) & (US$ Million)

Table 26. Global Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Type (2019-2024)

Table 27. Global Cystic Fibrosis (CF) Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 28. Global Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Type (2025-2030)

Table 29. Global Cystic Fibrosis (CF) Therapeutics Market Size by Application (2019-2024) & (US$ Million)

Table 30. Global Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Application (2019-2024)

Table 31. Global Cystic Fibrosis (CF) Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 32. Global Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Application (2025-2030)

Table 33. North America Cystic Fibrosis (CF) Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 34. North America Cystic Fibrosis (CF) Therapeutics Market Size by Country (2019-2024) & (US$ Million)

Table 35. North America Cystic Fibrosis (CF) Therapeutics Market Size by Country (2025-2030) & (US$ Million)

Table 36. Europe Cystic Fibrosis (CF) Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 37. Europe Cystic Fibrosis (CF) Therapeutics Market Size by Country (2019-2024) & (US$ Million)

Table 38. Europe Cystic Fibrosis (CF) Therapeutics Market Size by Country (2025-2030) & (US$ Million)

Table 39. Asia-Pacific Cystic Fibrosis (CF) Therapeutics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 40. Asia-Pacific Cystic Fibrosis (CF) Therapeutics Market Size by Region (2019-2024) & (US$ Million)

Table 41. Asia-Pacific Cystic Fibrosis (CF) Therapeutics Market Size by Region (2025-2030) & (US$ Million)

Table 42. Latin America Cystic Fibrosis (CF) Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 43. Latin America Cystic Fibrosis (CF) Therapeutics Market Size by Country (2019-2024) & (US$ Million)

Table 44. Latin America Cystic Fibrosis (CF) Therapeutics Market Size by Country (2025-2030) & (US$ Million)

Table 45. Middle East & Africa Cystic Fibrosis (CF) Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 46. Middle East & Africa Cystic Fibrosis (CF) Therapeutics Market Size by Country (2019-2024) & (US$ Million)

Table 47. Middle East & Africa Cystic Fibrosis (CF) Therapeutics Market Size by Country (2025-2030) & (US$ Million)

Table 48. Vertex Pharmaceuticalsorporated Company Detail

Table 49. Vertex Pharmaceuticalsorporated Business Overview

Table 50. Vertex Pharmaceuticalsorporated Cystic Fibrosis (CF) Therapeutics Product

Table 51. Vertex Pharmaceuticalsorporated Revenue in Cystic Fibrosis (CF) Therapeutics Business (2019-2024) & (US$ Million)

Table 52. Vertex Pharmaceuticalsorporated Recent Development

Table 53. Gilead Company Detail

Table 54. Gilead Business Overview

Table 55. Gilead Cystic Fibrosis (CF) Therapeutics Product

Table 56. Gilead Revenue in Cystic Fibrosis (CF) Therapeutics Business (2019-2024) & (US$ Million)

Table 57. Gilead Recent Development

Table 58. AbbVie, Company Detail

Table 59. AbbVie, Business Overview

Table 60. AbbVie, Cystic Fibrosis (CF) Therapeutics Product

Table 61. AbbVie, Revenue in Cystic Fibrosis (CF) Therapeutics Business (2019-2024) & (US$ Million)

Table 62. AbbVie, Recent Development

Table 63. Novartis AG Company Detail

Table 64. Novartis AG Business Overview

Table 65. Novartis AG Cystic Fibrosis (CF) Therapeutics Product

Table 66. Novartis AG Revenue in Cystic Fibrosis (CF) Therapeutics Business (2019-2024) & (US$ Million)

Table 67. Novartis AG Recent Development

Table 68. F. Hoffmann-La Roche Ltd Company Detail

Table 69. F. Hoffmann-La Roche Ltd Business Overview

Table 70. F. Hoffmann-La Roche Ltd Cystic Fibrosis (CF) Therapeutics Product

Table 71. F. Hoffmann-La Roche Ltd Revenue in Cystic Fibrosis (CF) Therapeutics Business (2019-2024) & (US$ Million)

Table 72. F. Hoffmann-La Roche Ltd Recent Development

Table 73. Alaxia Company Detail

Table 74. Alaxia Business Overview

Table 75. Alaxia Cystic Fibrosis (CF) Therapeutics Product

Table 76. Alaxia Revenue in Cystic Fibrosis (CF) Therapeutics Business (2019-2024) & (US$ Million)

Table 77. Alaxia Recent Development

Table 78. Merck & Co. Company Detail

Table 79. Merck & Co. Business Overview

Table 80. Merck & Co. Cystic Fibrosis (CF) Therapeutics Product

Table 81. Merck & Co. Revenue in Cystic Fibrosis (CF) Therapeutics Business (2019-2024) & (US$ Million)

Table 82. Merck & Co. Recent Development

Table 83. AIT (Advanced Inhalation Therapies) Company Detail

Table 84. AIT (Advanced Inhalation Therapies) Business Overview

Table 85. AIT (Advanced Inhalation Therapies) Cystic Fibrosis (CF) Therapeutics Product

Table 86. AIT (Advanced Inhalation Therapies) Revenue in Cystic Fibrosis (CF) Therapeutics Business (2019-2024) & (US$ Million)

Table 87. AIT (Advanced Inhalation Therapies) Recent Development

Table 88. ALLERGAN Company Detail

Table 89. ALLERGAN Business Overview

Table 90. ALLERGAN Cystic Fibrosis (CF) Therapeutics Product

Table 91. ALLERGAN Revenue in Cystic Fibrosis (CF) Therapeutics Business (2019-2024) & (US$ Million)

Table 92. ALLERGAN Recent Development

Table 93. AstraZeneca Company Detail

Table 94. AstraZeneca Business Overview

Table 95. AstraZeneca Cystic Fibrosis (CF) Therapeutics Product

Table 96. AstraZeneca Revenue in Cystic Fibrosis (CF) Therapeutics Business (2019-2024) & (US$ Million)

Table 97. AstraZeneca Recent Development

Table 98. Teva Pharmaceutical Industries Ltd Company Detail

Table 99. Teva Pharmaceutical Industries Ltd Business Overview

Table 100. Teva Pharmaceutical Industries Ltd Cystic Fibrosis (CF) Therapeutics Product

Table 101. Teva Pharmaceutical Industries Ltd Revenue in Cystic Fibrosis (CF) Therapeutics Business (2019-2024) & (US$ Million)

Table 102. Teva Pharmaceutical Industries Ltd Recent Development

Table 103. Alcresta Company Detail

Table 104. Alcresta Business Overview

Table 105. Alcresta Cystic Fibrosis (CF) Therapeutics Product

Table 106. Alcresta Revenue in Cystic Fibrosis (CF) Therapeutics Business (2019-2024) & (US$ Million)

Table 107. Alcresta Recent Development

Table 108. Research Programs/Design for This Report

Table 109. Key Data Information from Secondary Sources

Table 110. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Cystic Fibrosis (CF) Therapeutics Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Cystic Fibrosis (CF) Therapeutics Market Share by Type: 2023 VS 2030

Figure 3. Pancreatic enzyme supplements Features

Figure 4. Mucolytics Features

Figure 5. Bronchodilators Features

Figure 6. CFTR modulators Features

Figure 7. Global Cystic Fibrosis (CF) Therapeutics Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 8. Global Cystic Fibrosis (CF) Therapeutics Market Share by Application: 2023 VS 2030

Figure 9. Oral drugs Case Studies

Figure 10. Inhaled drugs Case Studies

Figure 11. Cystic Fibrosis (CF) Therapeutics Report Years Considered

Figure 12. Global Cystic Fibrosis (CF) Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 13. Global Cystic Fibrosis (CF) Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 14. Global Cystic Fibrosis (CF) Therapeutics Market Share by Region: 2023 VS 2030

Figure 15. Global Cystic Fibrosis (CF) Therapeutics Market Share by Players in 2023

Figure 16. Global Top Cystic Fibrosis (CF) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cystic Fibrosis (CF) Therapeutics as of 2023)

Figure 17. The Top 10 and 5 Players Market Share by Cystic Fibrosis (CF) Therapeutics Revenue in 2023

Figure 18. North America Cystic Fibrosis (CF) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 19. North America Cystic Fibrosis (CF) Therapeutics Market Share by Country (2019-2030)

Figure 20. United States Cystic Fibrosis (CF) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 21. Canada Cystic Fibrosis (CF) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 22. Europe Cystic Fibrosis (CF) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. Europe Cystic Fibrosis (CF) Therapeutics Market Share by Country (2019-2030)

Figure 24. Germany Cystic Fibrosis (CF) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. France Cystic Fibrosis (CF) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. U.K. Cystic Fibrosis (CF) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. Italy Cystic Fibrosis (CF) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. Russia Cystic Fibrosis (CF) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. Nordic Countries Cystic Fibrosis (CF) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Asia-Pacific Cystic Fibrosis (CF) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Asia-Pacific Cystic Fibrosis (CF) Therapeutics Market Share by Region (2019-2030)

Figure 32. China Cystic Fibrosis (CF) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Japan Cystic Fibrosis (CF) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. South Korea Cystic Fibrosis (CF) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. Southeast Asia Cystic Fibrosis (CF) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. India Cystic Fibrosis (CF) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. Australia Cystic Fibrosis (CF) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. Latin America Cystic Fibrosis (CF) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. Latin America Cystic Fibrosis (CF) Therapeutics Market Share by Country (2019-2030)

Figure 40. Mexico Cystic Fibrosis (CF) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Brazil Cystic Fibrosis (CF) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Middle East & Africa Cystic Fibrosis (CF) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Middle East & Africa Cystic Fibrosis (CF) Therapeutics Market Share by Country (2019-2030)

Figure 44. Turkey Cystic Fibrosis (CF) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Saudi Arabia Cystic Fibrosis (CF) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. Vertex Pharmaceuticalsorporated Revenue Growth Rate in Cystic Fibrosis (CF) Therapeutics Business (2019-2024)

Figure 47. Gilead Revenue Growth Rate in Cystic Fibrosis (CF) Therapeutics Business (2019-2024)

Figure 48. AbbVie, Revenue Growth Rate in Cystic Fibrosis (CF) Therapeutics Business (2019-2024)

Figure 49. Novartis AG Revenue Growth Rate in Cystic Fibrosis (CF) Therapeutics Business (2019-2024)

Figure 50. F. Hoffmann-La Roche Ltd Revenue Growth Rate in Cystic Fibrosis (CF) Therapeutics Business (2019-2024)

Figure 51. Alaxia Revenue Growth Rate in Cystic Fibrosis (CF) Therapeutics Business (2019-2024)

Figure 52. Merck & Co. Revenue Growth Rate in Cystic Fibrosis (CF) Therapeutics Business (2019-2024)

Figure 53. AIT (Advanced Inhalation Therapies) Revenue Growth Rate in Cystic Fibrosis (CF) Therapeutics Business (2019-2024)

Figure 54. ALLERGAN Revenue Growth Rate in Cystic Fibrosis (CF) Therapeutics Business (2019-2024)

Figure 55. AstraZeneca Revenue Growth Rate in Cystic Fibrosis (CF) Therapeutics Business (2019-2024)

Figure 56. Teva Pharmaceutical Industries Ltd Revenue Growth Rate in Cystic Fibrosis (CF) Therapeutics Business (2019-2024)

Figure 57. Alcresta Revenue Growth Rate in Cystic Fibrosis (CF) Therapeutics Business (2019-2024)

Figure 58. Bottom-up and Top-down Approaches for This Report

Figure 59. Data Triangulation

Figure 60. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global HFCWO Vest Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-6I14576

Thu Jul 25 00:00:00 UTC 2024

Add to Cart

Global Tumor Diagnosis Solutions Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-21H12722

Thu Jul 25 00:00:00 UTC 2024

Add to Cart

Global SGLT2 Inhibitors Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-25F12438

Thu Jul 25 00:00:00 UTC 2024

Add to Cart

Global Hepatitis A immunoglobulin Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-17D12859

Thu Jul 25 00:00:00 UTC 2024

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions